Loading…
ACADIA Pharmaceuticals Inc. is projected to rise to $37.24 by 2027, a +40% move from its current price of $26.55. ACAD is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $26.15 | $26.55 | $26.94 | -0.02% |
| Aug 2 | $25.99 | $26.54 | $27.10 | -0.04% |
| Aug 3 | $25.86 | $26.54 | $27.23 | -0.06% |
| Aug 4 | $25.75 | $26.53 | $27.33 | -0.07% |
| Aug 5 | $25.66 | $26.53 | $27.42 | -0.09% |
| Aug 6 | $25.57 | $26.52 | $27.50 | -0.11% |
| Aug 7 | $25.49 | $26.52 | $27.58 | -0.13% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $25.49 | $26.52 | $27.58 | -0.13% |
| Week 2 | $25.05 | $26.48 | $27.99 | -0.26% |
| Week 3 | $24.71 | $26.45 | $28.31 | -0.39% |
| Week 4 | $24.42 | $26.41 | $28.57 | -0.52% |
| Week 5 | $24.16 | $26.38 | $28.80 | -0.64% |
| Week 6 | $23.93 | $26.35 | $29.00 | -0.77% |
| Week 7 | $23.72 | $26.31 | $29.19 | -0.90% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
ACADIA Pharmaceuticals Inc. is a healthcare biopharmaceutical company focused on the development and commercialization of medicines for neurological and rare diseases in North America. Its portfolio includes NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis, and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat Rett syndrome by reducing neuroinflammation and supporting synaptic function.
The company was formerly known as Receptor Technologies, Inc. and changed its name to ACADIA Pharmaceuticals Inc. in 1997. ACADIA was incorporated in 1993 and is headquartered in San Diego, California.
ACADIA Pharmaceuticals Inc. (ACAD) is currently trading at $25.39 with a market capitalization of $4.35B. It is ranked 1398 by market data. The stock sits in a broadly bullish technical setting, with RSI(14) at 60, a 50-day simple moving average of $23.18 and a 200-day simple moving average of $23.50.
Near-term support is at $20.94 and resistance at $26.41. Over the last 30 days, the price has traded within a range of $22.90 to $28.15, and the stock shows an annualized volatility of 30%. The price outlook from the forecast shows upside across multiple years, with the 2026 average price at $25.39 and a 2030 average of $50.65, rising further to $154.59 by 2040 and $265.39 by 2050, accompanied by increasing ROIs from 0 in 2026 to 99.5 by 2030, 508.9 by 2040 and 945.3 by 2050.
A major floor 24.9% below — a decisive break under it would weaken the trend.
The nearest floor, 18.6% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 12.4% above — clearing it would confirm fresh momentum.
Key ACAD support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ACAD market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $25.83 | Buy | $26.01 | Buy |
| MA 10 | $25.50 | Buy | $25.73 | Buy |
| MA 20 | $25.71 | Buy | $25.33 | Buy |
| MA 50 | $23.53 | Buy | $24.21 | Buy |
| MA 100 | $22.66 | Buy | $23.58 | Buy |
| MA 200 | $23.61 | Buy | $23.15 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 67.02 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 130.17 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | -0.04 | Sell |
| ROC (12) | 4.16 | Buy |
| Bollinger %B (20,2) | 0.91 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.41 | Buy |
| Awesome (5,34) | 1.27 | Buy |
| Ultimate (7,14,28) | 68.05 | Neutral |
| Momentum (10) | 0.92 | Buy |
| Aroon Osc (25) | 100.00 | Buy |
| Hull MA (9) | 26.43 | Buy |
| ADX (14) | 24.99 | Buy |
| ATR (14) | 0.35 | Info |
The 30-day technical picture is broadly bullish, reflected in a bullish sentiment reading and an RSI of 60. The stock trades above the 50-day and 200-day moving averages, at $23.18 and $23.50 respectively, signaling constructive intermediate momentum. Support sits at $20.94, with resistance at $26.41, framing a near-term map for trading decisions.
The 30-day price range spans from $22.90 to $28.15, indicating elevated volatility but an overall uptrend bias.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $20.32 | $26.55 | $32.90 | 0% | Neutral | |
| $30.53 | $37.24 | $47.46 | +40% | Bullish | |
| $35.68 | $44.35 | $58.07 | +67% | Bullish | |
| $38.79 | $48.95 | $65.48 | +84% | Bullish | |
| $43.45 | $55.59 | $75.71 | +109% | Bullish | |
| $46.99 | $60.86 | $84.20 | +129% | Bullish | |
| $53.18 | $69.65 | $97.74 | +162% | Bullish | |
| $63.05 | $83.45 | $118.64 | +214% | Bullish | |
| $72.75 | $97.25 | $139.91 | +266% | Bullish | |
| $80.60 | $108.76 | $158.22 | +310% | Bullish | |
| $129.34 | $182.05 | $277.58 | +586% | Bullish | |
| $210.59 | $317.93 | $519.67 | +11.0x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $20.32 | $26.55 | $30.92 | +0.00% |
| August 2026 | $22.47 | $26.20 | $31.14 | -1.31% |
| September 2026 | $22.26 | $26.11 | $31.31 | -0.36% |
| October 2026 | $22.78 | $26.84 | $32.43 | +2.79% |
| November 2026 | $22.89 | $27.06 | $32.90 | +0.85% |
| December 2026 | $22.68 | $26.92 | $32.90 | -0.55% |
Click any year to see its month-by-month ACAD forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The ACAD price prediction for 2026 points to an average of $26.55 (low $20.32, high $32.90) — a potential gain of 0% on today's $26.55. Price action looks broadly range-bound.
In 2027, ACAD is projected to trade between $30.53 and $47.46, averaging $37.24 — a potential gain of +40% from today's $26.55. That is up +40% on the projected 2026 average. Buyers look set to stay in control over this stretch.
ACADIA Pharmaceuticals Inc.'s 2028 outlook centres on $44.35, within a $35.68 to $58.07 range. That is up +19% on the projected 2027 average. That marks a +67% change versus current levels. Momentum favours further upside here.
By 2029, ACAD could reach as high as $65.48, with a base case around $48.95 and support toward $38.79 — roughly +84% from $26.55. Buyers look set to stay in control over this stretch.
Expect ACAD to range from $43.45 to $75.71 through 2030. The $55.59 average target implies a +109% move from current prices. That is up +14% on the projected 2029 average. Momentum favours further upside here.
The ACAD price prediction for 2031 points to an average of $60.86 (low $46.99, high $84.20) — a potential gain of +129% on today's $26.55. Buyers look set to stay in control over this stretch.
In 2032, ACAD is projected to trade between $53.18 and $97.74, averaging $69.65 — a potential gain of +162% from today's $26.55. That is up +14% on the projected 2031 average. Momentum favours further upside here.
ACADIA Pharmaceuticals Inc.'s 2033 outlook centres on $83.45, within a $63.05 to $118.64 range. That is up +20% on the projected 2032 average. That marks a +214% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, ACAD could reach as high as $139.91, with a base case around $97.25 and support toward $72.75 — roughly +266% from $26.55. Momentum favours further upside here.
Expect ACAD to range from $80.60 to $158.22 through 2035. The $108.76 average target implies a +310% move from current prices. That is up +12% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The ACAD price prediction for 2040 points to an average of $182.05 (low $129.34, high $277.58) — a potential gain of +586% on today's $26.55. Momentum favours further upside here.
In 2050, ACAD is projected to trade between $210.59 and $519.67, averaging $317.93 — a potential gain of +11.0x from today's $26.55. That is up +75% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in ACAD today (≈ 37.664783 ACAD) could be worth
$11,974.59
+$10,974.59 (+1097%) by 2050 · US Dollar
Based on the average projected ACAD price of $317.93 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ACADwould be worth at today's price.
$1,000 invested in ACAD on Jul 30, 2025 (≈ 42.498936 ACAD) would be worth
$1,128.35
+$128.35 (+12.8%) today · 1.13× · US Dollar
Based on a ACAD entry price of $23.53 vs. today's $26.55.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $24.83 | $1,069.27 | +6.9% |
| 1 month ago | $25.3 | $1,049.41 | +4.9% |
| 3 months ago | $21.95 | $1,209.57 | +21.0% |
| 6 months ago | $25.13 | $1,056.51 | +5.7% |
| 1 year ago | $23.53 | $1,128.35 | +12.8% |
| All time (5.0y) ago | $21 | $1,264.29 | +26.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ACAD forecast.
Our base-case forecast reaches $53.00 around 2030.
Implied market cap at $53.00: $9.08B
The multi-year forecast points to substantial upside, with the average price rising from $25.39 in 2026 to $50.65 in 2030, then to $154.59 in 2040 and $265.39 in 2050. The corresponding ROIs are 0 in 2026, 99.5 by 2030, 508.9 by 2040 and 945.3 by 2050, with bullish sentiment accompanying the longer-horizon outlook. These targets imply a strong, longer-term appreciation trajectory, albeit with wide potential ranges (e.g., 2030 min $39.58, max $68.98; 2040 min $109.82, max $235.73; 2050 min $175.78, max $433.82).
While the line of sight appears favorable, investors should consider the inherent uncertainty and the 30% annualized volatility as factors that can influence outcomes. The 2026 forecast anchor also suggests an average price identical to the current price, reinforcing the idea of a base-to-upside expansion over time.
Tap a question to reveal the answer.
The forecast shows an average price of $50.65 in 2030, with a minimum of $39.58 and a maximum of $68.98, and a forecasted ROI of 99.5. The sentiment for 2030 is bullish.
The forecast depicts a bullish long-term trajectory, with average prices rising through 2027 ($34.96), 2028 ($41.06), 2029 ($44.83), and into 2030 ($50.65), accompanied by rising ROIs (e.g., 37.7 in 2027, 99.5 in 2030) and higher through 2040 and 2050 (508.9 and 945.3 respectively). These figures indicate upside potential but are not guarantees and reflect projections.
Yes. The forecast shows a 2033 maximum price of $104.68, indicating the asset can exceed $100 in its projected path.
Current price is $25.39 and market cap is $4.35B.
The 30-day price range is $22.90 to $28.15. Nearby support is at $20.94 and resistance at $26.41, with a bullish technical backdrop and RSI at 60.
ACADIA Pharmaceuticals Inc. Community Discussion
0Share your ACADIA Pharmaceuticals Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.